Predicting mortality and detecting severe disease
AssigneeCritical Care Diagnostics, Inc.
InventorsJames V. Snider, Sven Jacobson
Life of this patent
Estimating the term…
Abstract
Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.
Claims18
A method for evaluating the risk of death within a year for a subject who has undiagnosed shortness of breath, undiagnosed chest pain, or undiagnosed chest discomfort, the method comprising:
- obtaining a biological sample from the subject;
- determining a level of soluble secreted Growth Stimulation-Expressed Gene 2 (ST2) protein in the sample;
- and
- comparing the level of ST2 in the sample to a reference level of ST2;
- wherein the presence of a significantly higher level of ST2 in the sample as compared to the reference level indicates that the subject has an increased risk of death within a year.
A method for evaluating the risk of death within a year for a subject who has undiagnosed shortness of breath, undiagnosed chest pain, or undiagnosed chest discomfort, the method comprising:
- obtaining a biological sample from the subject;
- determining a level of soluble secreted Growth Stimulation-Expressed Gene 2 (ST2) protein in the sample;
- and
- comparing the level of ST2 in the sample to a reference level of ST2,
- wherein the reference level is about 0.2 to 0.3 ng/ml of serum, and a level in the sample that is greater than or equal to the reference level indicates that the subject has an elevated risk of death within one year, compared to a subject with a ST2 level below the reference level.
A method for evaluating the risk of death within a year for a subject who has undiagnosed shortness of breath, undiagnosed chest pain, or undiagnosed chest discomfort, the method comprising:
- obtaining a biological sample from the subject;
- determining a level of soluble secreted Growth Stimulation-Expressed Gene 2 (ST2) protein in the sample;
- determining a level of an adjunct biomarker selected from the group consisting of BUN, NT-proBNP, proBNP, and BNP in the sample, and
- comparing the level of ST2 in the sample to a threshold level of ST2,
- comparing the level of the adjunct biomarker in the sample to an adjunct biomarker threshold level;
- wherein the presence of a level of the adjunct biomarker in the sample that is greater than or equal to the adjunct biomarker threshold, in combination with a level of ST2 in the sample that is greater than or equal to the threshold level of ST2, indicates whether the subject has an increased risk of death within a year.
A method for evaluating the risk of death within a year for a subject who has undiagnosed shortness of breath, undiagnosed chest pain, or undiagnosed chest discomfort, the method comprising:
- obtaining a biological sample from the subject;
- determining a level of soluble secreted Growth Stimulation-Expressed Gene 2 (ST2) protein in the sample;
- and
- comparing the level of ST2 in the sample to a threshold level of ST2;
- wherein the presence of a level of ST2 in the sample that is greater than or equal to the threshold level of ST2 indicates that the subject has an increased risk of death within a year.
Dependencies are inferred from the claim text.